Abbvie Inc
NYSE: ABBV
$178.34
+$1.39 (+0.8%)
Real Time Data Delayed 15 Min.
ABBV Articles
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political purposes, you may want to start buying.
Published:
Last Updated:
AbbVie reported mixed fourth-quarter financial results after the markets closed Thursday.
Published:
Last Updated:
AbbVie is scheduled to report its fourth-quarter financial results before the markets open Friday.
Published:
Last Updated:
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated:
The Wall Street firms we cover are well aware of investor anxiety, yet they, unlike financial media talking heads, realize investors can’t just go to cash with a snap of their fingers.
Published:
Last Updated:
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
In a new research note, Jefferies makes the case that earnings could give a lift to the sagging market, and with low expectations, the lift could be solid.
Published:
Last Updated:
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Published:
Last Updated:
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
The Franchise Picks list makes sense for solid growth investors looking for total return. Many of the stocks pay good dividends and have upside price potential.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Published:
Last Updated:
Buying high-yielding blue chips for 2016 makes good sense. The Federal Reserve interest rate increases over the next two years are expected to remain very small and very measured.
Published:
Last Updated:
You may want to avoid these stocks over the next few months.
Published:
Last Updated: